Aguirre-Cruz L, Sotelo J
Neuroimmunology Department, National Institute of Neurology, México D.F., Mexico.
J Parasitol. 1998 Feb;84(1):163-4.
In a previous report, we showed that addition of colchicine to cultures of glial cells infected with Toxoplasma gondii decreased the number of parasites by up to 80%. To provide support for potential therapeutic use of colchicine in toxoplasmosis, a murine model of T. gondii infection was used. Mice infected with pure RH T. gondii tachyzoites (from 2,233 to 25,000 parasites) were treated daily with either pyrimethamine (80 or 51 mg/kg), colchicine (10 mg/kg), pyrimethamine-colchicine, or vehicle (controls). Survival rates were lower in animals treated with colchicine (from 40% to 27%) and pyrimethamine-colchicine (from 73% to 41%) than in animals treated with pyrimethamine alone (from 100% to 73%). There was no extension of mean survival time in animals treated with colchicine compared to controls. These results demonstrate that colchicine does not improve the course of acute toxoplasmosis in mice, and it is detrimental rather than beneficial at the regimen tested.
在之前的一份报告中，我们表明，向感染了刚地弓形虫的神经胶质细胞培养物中添加秋水仙碱可使寄生虫数量减少多达80%。为了支持秋水仙碱在弓形虫病治疗中的潜在用途，使用了刚地弓形虫感染的小鼠模型。用纯RH刚地弓形虫速殖子（2233至25000个寄生虫）感染的小鼠，每天分别用乙胺嘧啶（80或51mg/kg）、秋水仙碱（10mg/kg）、乙胺嘧啶-秋水仙碱或赋形剂（对照组）进行治疗。与单独用乙胺嘧啶治疗的动物（从100%至73%）相比，用秋水仙碱治疗的动物（从40%至27%）和用乙胺嘧啶-秋水仙碱治疗的动物（从73%至41%）的存活率较低。与对照组相比，用秋水仙碱治疗的动物的平均存活时间没有延长。这些结果表明，秋水仙碱并不能改善小鼠急性弓形虫病的病程，在所测试的方案中，它是有害而非有益的。
